National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin

被引:72
作者
Takakura, S
Fujihara, N
Saito, T
Kudo, T
Iinuma, Y
Ichiyama, S
机构
[1] Kyoto Univ, Grad Sch Med, Dept Clin Lab Med, Sakyo Ku, Kyoto 6068507, Japan
[2] KKR Takamatsu Hosp, Dept Clin Lab Med, Kagawa 7600018, Japan
基金
日本学术振兴会;
关键词
candidaemia; triazoles; echinocandins;
D O I
10.1093/jac/dkh053
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The aim of this study was to evaluate species distribution and antifungal susceptibility of Candida blood isolates in Japan. Methods: In a 1 year surveillance programme, 535 Candida blood isolates were collected. Identification of species was followed by examination with the broth microdilution method, as described in NCCLS M27-A2, of antifungal susceptibility to six agents, including voriconazole and micafungin, with readings after 24 and 48 h of incubation. Results: The overall species distribution was: 41% Candida albicans, 23% Candida parapsilosis, 18% Candida glabrata, 12% Candida tropicalis and 2% Candida krusei. The concentrations of fluconazole necessary to inhibit 90% of the isolates (MIC90) at 24/48 h were 0.25/1 mg/L for C. albicans, 0.5/2 mg/L for C. parapsilosis, 4/32 mg/L for C. glabrata and 4/>128 mg/L for C. tropicalis. Percentages of fluconazole resistance were 1.8% for C. albicans, 0.8% for C. parapsilosis, 5.2% for C. glabrata and 3.2% for C. tropicalis, taking the tendency of trailing growth of C. tropicalis into account. MIC90 of voriconazole was 0.5 mg/L, although 35% of isolates less susceptible (greater than or equal to16 mg/L) to fluconazole showed resistance (greater than or equal to2 mg/L). Micafungin was very active against all species (MIC90, 0.03 mg/L) except for C. parapsilosis (MIC90, 2 mg/L). Conclusions: These data suggest that, in Japan, the species distribution of Candida bloodstream infections and the fluconazole resistance rate are similar to those reported previously in North America and Europe. Voriconazole and micafungin appear to have strong in vitro activity against Candida blood isolates, although continuing surveillance and further clinical research are needed.
引用
收藏
页码:283 / 289
页数:7
相关论文
共 37 条
[1]   Predictors of adverse outcome in cancer patients with candidemia [J].
Anaissie, EJ ;
Rex, JH ;
Uzun, Ö ;
Vartivarian, S .
AMERICAN JOURNAL OF MEDICINE, 1998, 104 (03) :238-245
[2]  
[Anonymous], 2002, M27A2 CLSI
[3]   Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis [J].
Arthington-Skaggs, BA ;
Warnock, DW ;
Morrison, CJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2081-2085
[4]   GENOTYPIC VARIATION AND SLIME PRODUCTION AMONG BLOOD AND CATHETER ISOLATES OF CANDIDA-PARAPSILOSIS [J].
BRANCHINI, ML ;
PFALLER, MA ;
RHINECHALBERG, J ;
FREMPONG, T ;
ISENBERG, HD .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (02) :452-456
[5]   Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998:: Comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method [J].
Chryssanthou, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (11) :4181-4183
[6]   Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species [J].
Chryssanthou, E ;
Cuenca-Estrella, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) :3841-3844
[7]   Candidiasis: The emergence of a novel species, Candida dubliniensis [J].
Coleman, DC ;
Sullivan, DJ ;
Bennett, DE ;
Moran, GP ;
Barry, HJ ;
Shanley, DB .
AIDS, 1997, 11 (05) :557-567
[8]   Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain [J].
Cuenca-Estrella, M ;
Díaz-Guerra, TM ;
Mellado, E ;
Monzón, A ;
Rodríguez-Tudela, JL .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (06) :432-435
[9]   Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study [J].
Diekema, DJ ;
Messer, SA ;
Brueggemann, AB ;
Coffman, SL ;
Doern, GV ;
Herwaldt, LA ;
Pfaller, MA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (04) :1298-1302
[10]   Nosocomial bloodstream infections in United States hospitals: A three-year analysis [J].
Edmond, MB ;
Wallace, SE ;
McClish, DK ;
Pfaller, MA ;
Jones, RN ;
Wenzel, RP .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :239-244